Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone therapy, comparable to Menarini's Orserdu.

Bioscience & Technology Business Center The University of Kansas Lawrence, Kansas Latest All News Special In Focus Channels AI Bioregnum Biotech Voices Cell/Gene Tx China Coronavirus Deals ...